41 documents

Read All
07:00 , May 25, 2015 |  BC Week In Review  |  Company News

Taxus Cardium, Shenzhen Qianhai Taxus Insdustry Capital Management deal

Taxus Cardium granted Shenzhen the first right to negotiate for an exclusive license to develop and commercialize three Taxus products in Asian countries. The products include Generx alferminogene tadenovec, an adenoviral vector carrying the...
Read More
07:00 , May 4, 2015 |  BC Week In Review  |  Company News

Taxus Cardium, Dr. Reddy’s Laboratories Ltd. deal

Taxus granted Dr. Reddy’s exclusive rights to co-develop and commercialize Generx cardionovo alferminogene tadenovec in the Commonwealth of Independent States (CIS), Venezuela, Vietnam and Myanmar. Dr. Reddy’s also has the right of first...
Read More
08:00 , Feb 16, 2015 |  BC Week In Review  |  Clinical News

Generx cardionovo alferminogene tadenovec: Interim Phase III data

Interim data from 11 patients with myocardial ischemia due to coronary artery disease (CAD) in the open-label, Russian Phase III ASPIRE trial showed that an intracoronary infusion of Generx led to a 24.4% improvement in...
Read More
07:00 , Apr 7, 2014 |  BioCentury  |  Finance

1Q Stock Wrap-Up: Small but mighty

Despite a correction at the end of March, all biotech market cap segments finished the first quarter in positive territory. Microcaps set the pace with a 10% gain, while large caps added 7% and were...
Read More
08:00 , Mar 6, 2014 |  BC Innovations  |  Targets & Mechanisms

Heart cells: no longer undivided

The inability of adult heart cells to divide rapidly enough to repair cardiac damage has been a major impediment to regenerating heart tissue and preventing fibrosis after myocardial infarction. Now, a U.S. team has used...
Read More
07:00 , Mar 26, 2012 |  BC Week In Review  |  Clinical News

Generx cardionovo alferminogene tadenovec: Phase III started

Cardium began the open-label, Russian Phase III ASPIRE trial to evaluate Generx administered through a standard cardiac infusion catheter in about 100 patients with myocardial ischemia due to coronary artery disease. Cardium Therapeutics Inc. (NYSE-A:CXM),...
Read More
08:00 , Feb 13, 2012 |  BC Week In Review  |  Clinical News

Generx cardionovo alferminogene tadenovec: Phase III start

This quarter, Cardium will begin the Russian Phase III ASPIRE trial to evaluate Generx administered through a standard cardiac infusion catheter in about 100 patients with myocardial ischemia due to coronary artery disease. Cardium Therapeutics...
Read More
07:00 , Sep 3, 2007 |  BC Week In Review  |  Clinical News

Generx alferminogene: Phase IIb/III data

Pooled data from 2 double-blind, U.S. and international Phase IIb/III trials (AGENT-3 and AGENT-4) showed that a pre-specified subgroup of 72 women receiving the high dose of Ad5FGF4 had significant improvements vs. placebo on both...
Read More
07:00 , Jul 23, 2007 |  BC Week In Review  |  Clinical News

Generx alferminogene regulatory update

FDA granted Fast Track designation for CDTP's Generx alferminogene to treat myocardial ischemia. The adenoviral vector encoding fibroblast growth factor-4 (FGF-4) is in Phase III testing. Cardium Therapeutics Inc. (CDTP), San Diego, Calif.   Product: ...
Read More
07:00 , May 21, 2007 |  BC Week In Review  |  Clinical News

Generx alferminogene: Phase III started

CDTP started the double-blind, placebo-controlled, U.S. Phase III AWARE trial in about 300 female patients. Cardium Therapeutics Inc. (CDTP), San Diego, Calif.   Product: Generx alferminogene ( Ad5FGF4)   Business: Cardiovascular   Molecular target: NA   Description:...
Read More